TRATAMIENTO DE LA HEMOGLOBINURIA PAROXISTICA NOCTURNA CON GLOBULINA ANTILINFOCITARIA

Translated title of the contribution: Antilymphocyte globulin therapy for paroxysmal nocturnal hemoglobinuria

E. Sanchez-Valle, M. R. Morales-Polanco, E. Gomez-Morales, Laura Gutierrez, G. Gutierrez-Espindola, J. Pizzuto-Chavez

Research output: Contribution to journalArticle

Abstract

Objective. To evaluate the effectiveness of antilymphocyte globulin therapy (ALG) in patients with paroxysmal nocturnal hemoglobinuria (PNH). Design. Prospective, non-controlled trial. Setting. Hematology Service, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS, Mexico City. Patients. Six patients were included. The median age was 37.5 years and the male/female ratio was 1:1. All the patients had clinical disease consistent with PNH (hemolytic anemia with some degree of transient or persistent pancytopenia) and also erythrocytes with enhanced sensitivity to complement mediated lysis in vitro, as documented by either the Ham test or the sucrose lysis assay. The criterion for severity was the existence of continuous hemolysis in all and transfusion requirements of two or more packed red cells per month in four cases. Prior to ALG therapy, androgens and/or steroids had been given to five patients with no improvement. Intervention. A single batch of ALG was used during the trial (E 0034, Lymphoglobulin Merieux, Lyon, France). Patients received an infusion of 10 mg/kg per day in a 20 hours lapse during four consecutive days. Also 500 mg/day of methylprednisolone were started simultaneously with the ALG; it was given for seven days and was gradually tapered off and stopped on day 30. Measurements. The increases in hemoglobin, granulocytes and/or platelets as well as decreases in red cell transfusion requirements were used to evaluate the results of therapy. Results. Two patients suffered anaphylaxis after the first administration of ALG and were withdrawn from the study. Two of the four remaining patients responded, one response was total and the other minimal. The responses were transient, and no response was seen in the follow-up of 11-14 months. Conclusion. ALG therapy for PNH in the doses and time periods used by us had no beneficial effect in patients with a severe form of PNH.

Original languageSpanish
Pages (from-to)457-461
Number of pages5
JournalRevista de Investigacion Clinica
Volume45
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Paroxysmal Hemoglobinuria
Antilymphocyte Serum
Therapeutics
Pancytopenia
Hemolytic Anemia
Methylprednisolone
Anaphylaxis
Hematology
Hemolysis
Mexico
Granulocytes
Androgens
France
Sucrose
Hemoglobins
Blood Platelets
Erythrocytes
Steroids

Keywords

  • antilymphocyte globulin therapy
  • paroxysmal nocturnal hemoglobinuria

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sanchez-Valle, E., Morales-Polanco, M. R., Gomez-Morales, E., Gutierrez, L., Gutierrez-Espindola, G., & Pizzuto-Chavez, J. (1993). TRATAMIENTO DE LA HEMOGLOBINURIA PAROXISTICA NOCTURNA CON GLOBULINA ANTILINFOCITARIA. Revista de Investigacion Clinica, 45(5), 457-461.

TRATAMIENTO DE LA HEMOGLOBINURIA PAROXISTICA NOCTURNA CON GLOBULINA ANTILINFOCITARIA. / Sanchez-Valle, E.; Morales-Polanco, M. R.; Gomez-Morales, E.; Gutierrez, Laura; Gutierrez-Espindola, G.; Pizzuto-Chavez, J.

In: Revista de Investigacion Clinica, Vol. 45, No. 5, 1993, p. 457-461.

Research output: Contribution to journalArticle

Sanchez-Valle, E, Morales-Polanco, MR, Gomez-Morales, E, Gutierrez, L, Gutierrez-Espindola, G & Pizzuto-Chavez, J 1993, 'TRATAMIENTO DE LA HEMOGLOBINURIA PAROXISTICA NOCTURNA CON GLOBULINA ANTILINFOCITARIA', Revista de Investigacion Clinica, vol. 45, no. 5, pp. 457-461.
Sanchez-Valle E, Morales-Polanco MR, Gomez-Morales E, Gutierrez L, Gutierrez-Espindola G, Pizzuto-Chavez J. TRATAMIENTO DE LA HEMOGLOBINURIA PAROXISTICA NOCTURNA CON GLOBULINA ANTILINFOCITARIA. Revista de Investigacion Clinica. 1993;45(5):457-461.
Sanchez-Valle, E. ; Morales-Polanco, M. R. ; Gomez-Morales, E. ; Gutierrez, Laura ; Gutierrez-Espindola, G. ; Pizzuto-Chavez, J. / TRATAMIENTO DE LA HEMOGLOBINURIA PAROXISTICA NOCTURNA CON GLOBULINA ANTILINFOCITARIA. In: Revista de Investigacion Clinica. 1993 ; Vol. 45, No. 5. pp. 457-461.
@article{72e1db63268043ffb987111b14bdac0d,
title = "TRATAMIENTO DE LA HEMOGLOBINURIA PAROXISTICA NOCTURNA CON GLOBULINA ANTILINFOCITARIA",
abstract = "Objective. To evaluate the effectiveness of antilymphocyte globulin therapy (ALG) in patients with paroxysmal nocturnal hemoglobinuria (PNH). Design. Prospective, non-controlled trial. Setting. Hematology Service, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS, Mexico City. Patients. Six patients were included. The median age was 37.5 years and the male/female ratio was 1:1. All the patients had clinical disease consistent with PNH (hemolytic anemia with some degree of transient or persistent pancytopenia) and also erythrocytes with enhanced sensitivity to complement mediated lysis in vitro, as documented by either the Ham test or the sucrose lysis assay. The criterion for severity was the existence of continuous hemolysis in all and transfusion requirements of two or more packed red cells per month in four cases. Prior to ALG therapy, androgens and/or steroids had been given to five patients with no improvement. Intervention. A single batch of ALG was used during the trial (E 0034, Lymphoglobulin Merieux, Lyon, France). Patients received an infusion of 10 mg/kg per day in a 20 hours lapse during four consecutive days. Also 500 mg/day of methylprednisolone were started simultaneously with the ALG; it was given for seven days and was gradually tapered off and stopped on day 30. Measurements. The increases in hemoglobin, granulocytes and/or platelets as well as decreases in red cell transfusion requirements were used to evaluate the results of therapy. Results. Two patients suffered anaphylaxis after the first administration of ALG and were withdrawn from the study. Two of the four remaining patients responded, one response was total and the other minimal. The responses were transient, and no response was seen in the follow-up of 11-14 months. Conclusion. ALG therapy for PNH in the doses and time periods used by us had no beneficial effect in patients with a severe form of PNH.",
keywords = "antilymphocyte globulin therapy, paroxysmal nocturnal hemoglobinuria",
author = "E. Sanchez-Valle and Morales-Polanco, {M. R.} and E. Gomez-Morales and Laura Gutierrez and G. Gutierrez-Espindola and J. Pizzuto-Chavez",
year = "1993",
language = "Spanish",
volume = "45",
pages = "457--461",
journal = "Revista de Investigacion Clinica",
issn = "0034-8376",
publisher = "Instituto Nacional de la Nutricion Salvador Zubiran",
number = "5",

}

TY - JOUR

T1 - TRATAMIENTO DE LA HEMOGLOBINURIA PAROXISTICA NOCTURNA CON GLOBULINA ANTILINFOCITARIA

AU - Sanchez-Valle, E.

AU - Morales-Polanco, M. R.

AU - Gomez-Morales, E.

AU - Gutierrez, Laura

AU - Gutierrez-Espindola, G.

AU - Pizzuto-Chavez, J.

PY - 1993

Y1 - 1993

N2 - Objective. To evaluate the effectiveness of antilymphocyte globulin therapy (ALG) in patients with paroxysmal nocturnal hemoglobinuria (PNH). Design. Prospective, non-controlled trial. Setting. Hematology Service, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS, Mexico City. Patients. Six patients were included. The median age was 37.5 years and the male/female ratio was 1:1. All the patients had clinical disease consistent with PNH (hemolytic anemia with some degree of transient or persistent pancytopenia) and also erythrocytes with enhanced sensitivity to complement mediated lysis in vitro, as documented by either the Ham test or the sucrose lysis assay. The criterion for severity was the existence of continuous hemolysis in all and transfusion requirements of two or more packed red cells per month in four cases. Prior to ALG therapy, androgens and/or steroids had been given to five patients with no improvement. Intervention. A single batch of ALG was used during the trial (E 0034, Lymphoglobulin Merieux, Lyon, France). Patients received an infusion of 10 mg/kg per day in a 20 hours lapse during four consecutive days. Also 500 mg/day of methylprednisolone were started simultaneously with the ALG; it was given for seven days and was gradually tapered off and stopped on day 30. Measurements. The increases in hemoglobin, granulocytes and/or platelets as well as decreases in red cell transfusion requirements were used to evaluate the results of therapy. Results. Two patients suffered anaphylaxis after the first administration of ALG and were withdrawn from the study. Two of the four remaining patients responded, one response was total and the other minimal. The responses were transient, and no response was seen in the follow-up of 11-14 months. Conclusion. ALG therapy for PNH in the doses and time periods used by us had no beneficial effect in patients with a severe form of PNH.

AB - Objective. To evaluate the effectiveness of antilymphocyte globulin therapy (ALG) in patients with paroxysmal nocturnal hemoglobinuria (PNH). Design. Prospective, non-controlled trial. Setting. Hematology Service, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS, Mexico City. Patients. Six patients were included. The median age was 37.5 years and the male/female ratio was 1:1. All the patients had clinical disease consistent with PNH (hemolytic anemia with some degree of transient or persistent pancytopenia) and also erythrocytes with enhanced sensitivity to complement mediated lysis in vitro, as documented by either the Ham test or the sucrose lysis assay. The criterion for severity was the existence of continuous hemolysis in all and transfusion requirements of two or more packed red cells per month in four cases. Prior to ALG therapy, androgens and/or steroids had been given to five patients with no improvement. Intervention. A single batch of ALG was used during the trial (E 0034, Lymphoglobulin Merieux, Lyon, France). Patients received an infusion of 10 mg/kg per day in a 20 hours lapse during four consecutive days. Also 500 mg/day of methylprednisolone were started simultaneously with the ALG; it was given for seven days and was gradually tapered off and stopped on day 30. Measurements. The increases in hemoglobin, granulocytes and/or platelets as well as decreases in red cell transfusion requirements were used to evaluate the results of therapy. Results. Two patients suffered anaphylaxis after the first administration of ALG and were withdrawn from the study. Two of the four remaining patients responded, one response was total and the other minimal. The responses were transient, and no response was seen in the follow-up of 11-14 months. Conclusion. ALG therapy for PNH in the doses and time periods used by us had no beneficial effect in patients with a severe form of PNH.

KW - antilymphocyte globulin therapy

KW - paroxysmal nocturnal hemoglobinuria

UR - http://www.scopus.com/inward/record.url?scp=0027756797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027756797&partnerID=8YFLogxK

M3 - Article

C2 - 8134727

AN - SCOPUS:0027756797

VL - 45

SP - 457

EP - 461

JO - Revista de Investigacion Clinica

JF - Revista de Investigacion Clinica

SN - 0034-8376

IS - 5

ER -